Table 4.

Multivariable Cox model with MRD, early ibrutinib discontinuation, and their interaction as time-varying covariates in the IR arm and multivariable Cox model with baseline IGHV mutation status and MRD status as a time-varying covariate in the FCR arm

Estimated
HR		95% CIP
IR arm*    
 MRD (reference: <10−1) ≥10−1 6.50 2.50-16.87 <.001 
 Early discontinuation (reference: continuing ibrutinib) 19.09 7.50-48.58 <.001 
 Interaction (reference: <10−1 and continuing ibrutinib) ≥10−1 and off 0.30 0.07-1.22 .093 
FRC arm†    
 MRD detectable (reference: undetectable) 3.82 1.70-8.58 .0012 
 IGHV unmutated (reference: mutated) 1.72 0.76-3.90 .196 
Estimated
HR		95% CIP
IR arm*    
 MRD (reference: <10−1) ≥10−1 6.50 2.50-16.87 <.001 
 Early discontinuation (reference: continuing ibrutinib) 19.09 7.50-48.58 <.001 
 Interaction (reference: <10−1 and continuing ibrutinib) ≥10−1 and off 0.30 0.07-1.22 .093 
FRC arm†    
 MRD detectable (reference: undetectable) 3.82 1.70-8.58 .0012 
 IGHV unmutated (reference: mutated) 1.72 0.76-3.90 .196 
*

MRD status (with 10−1 as cutoff) at all 3 time points were considered in the model.

†

MRD status (detectable or not) at all 4 time points were considered in the model.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal